Zhejiang Doer Biologics Co., Ltd.

This study is testing an investigational injection called DR10624 to see if it can reduce liver fat and scarring in people with metabolic fatty liver disease (MASLD) who are at high risk. About 110 participants will receive either the drug or a placebo for 12 weeks, with research…